Chronic depression: Medication (Nefazodone) or psychotherapy (CBASP) is effective when the other is not

Department of Psychiatry and Behavioral Sciences, Stanford University School of Medicine, Stanford, CA 94305-5717, USA.
Archives of General Psychiatry (Impact Factor: 13.75). 06/2005; 62(5):513-20. DOI: 10.1001/archpsyc.62.5.513
Source: PubMed

ABSTRACT Although various strategies are available to manage nonresponders to an initial treatment for depression, no controlled trials address the utility of switching from an antidepressant medication to psychotherapy or vice versa.
To compare the responses of chronically depressed nonresponders to 12 weeks of treatment with either nefazodone or cognitive behavioral analysis system of psychotherapy (CBASP) who were crossed over to the alternate treatment (nefazodone, n = 79; CBASP, n = 61).
Crossover trial.
Twelve academic outpatient psychiatric centers.
There were 140 outpatients with chronic major depressive disorder; 92 (65.7%) were female, 126 (90.0%) were white, and the mean age was 43.1 years. Thirty participants dropped out of the study prematurely, 22 in the nefazodone group and 8 in the CBASP group.
Treatment lasted 12 weeks. The dosage of nefazodone was 100 to 600 mg/d; CBASP was provided twice weekly during weeks 1 through 4 and weekly thereafter.
The 24-item Hamilton Rating Scale for Depression, administered by raters blinded to treatment, the Clinician Global Impressions-Severity scale, and the 30-item Inventory for Depressive Symptomatology-Self-Report.
Analysis of the intent-to-treat sample revealed that both the switch from nefazodone to CBASP and the switch from from CBASP to nefazodone resulted in clinically and statistically significant improvements in symptoms. Neither the rates of response nor the rates of remission were significantly different when the groups of completers were compared. However, the switch to CBASP following nefazodone therapy was associated with significantly less attrition due to adverse events, which may explain the higher intent-to-treat response rate among those crossed over to CBASP (57% vs 42%).
Among chronically depressed individuals, CBASP appears to be efficacious for nonresponders to nefazodone, and nefazodone appears to be effective for CBASP nonresponders. A switch from an antidepressant medication to psychotherapy or vice versa appears to be useful for nonresponders to the initial treatment.

Download full-text


Available from: John C Markowitz, Jul 31, 2015
1 Follower
  • Source
    • "This near-doubling of rTMS efficacy over the last 4 years represents a significant advance towards the viability of rTMS as a firstline treatment for refractory depression. In this population, rTMS remission rates now match or exceed the 23e33% remission rates seen for an open-label second medication trial or cognitive therapy in patients failing a first medication trial in the STAR*D study [22], or the 35% response and 22% remission rates seen for patients switching to psychotherapy after failing an antidepressant medication [23]. At the same time, these advances also suggest that rTMS still has substantial scope for optimization, and that clinically meaningful improvements in rTMS efficacy may accrue with further refinements in technique. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Although rTMS is moving steadily into the mainstream as a treatment for medically refractory depression, its efficacy continues to lag behind that of more invasive neuromodulation treatments such as ECT or DBS. Here we review evidence to suggest that a fruitful, but neglected, strategy for improving rTMS efficacy may be to explore alternatives to the conventional stimulation target in the dorsolateral prefrontal cortex (DLPFC). The convergent evidence of lesion, stimulation, connectivity, and correlative neuroimaging studies suggests that the DLPFC may have a relatively peripheral role in mood regulation, at least compared to several alternative areas within the prefrontal cortex. In particular, we consider the evidence base in support of four new potential targets for rTMS in depression: dorsomedial prefrontal cortex (DMPFC), frontopolar cortex (FPC), ventromedial prefrontal cortex (VMPFC), and ventrolateral prefrontal cortex (VLPFC). Each of these regions enjoys broader support, from a more diverse evidence base, than the DLPFC in terms of its role in emotion regulation in major depression. We discuss the relative merits of each of these novel targets, including potential obstacles to stimulation using currently available technologies, and potential strategies for overcoming these obstacles. It is hoped that this detailed review will spur a more vigorous exploration of new targets for rTMS in depression. The use of new targets may help to propel rTMS across the threshold of efficacy required of a first-line treatment, to assume a more widespread role in the treatment of depressed mood.
    Brain Stimulation 09/2012; 6(3). DOI:10.1016/j.brs.2012.08.006 · 5.43 Impact Factor
  • Source
    • "Patients achieving less than full remission were randomized into phase 2. Full remission was defined by concomitantly meeting the following three conditions: a) ≥ 60% reduction in Hamilton Scale for Depression [HAM-D] score, b) a 24- item HAM-D total score less than 8, and c) no longer meeting DSM-IV criteria for MDD for 2 consecutive visits during weeks 6 through 12. Phase 2 participants all received the nextstep treatment in the pharmacotherapy algorithm and were randomly assigned to one of three treatment cells in a 2:2:1 ratio: to have CBASP or BSP added to their pharmacotherapy or to receive medication alone. The 12-week duration for phase 2 mirrored the length of treatment in a previous chronic depression study by our group (Keller et al., 2000; Schatzberg et al., 2005) and the STAR*D study (Thase et al., 2007). "
    [Show abstract] [Hide abstract]
    ABSTRACT: Depression is associated with poor social problem solving, and psychotherapies that focus on problem-solving skills are efficacious in treating depression. We examined the associations between treatment, social problem solving, and depression in a randomized clinical trial testing the efficacy of psychotherapy augmentation for chronically depressed patients who failed to fully respond to an initial trial of pharmacotherapy (Kocsis et al., 2009). Participants with chronic depression (n = 491) received cognitive-behavioral analysis system of psychotherapy (CBASP; McCullough, 2000), which emphasizes interpersonal problem solving, plus medication; brief supportive psychotherapy (BSP) plus medication; or medication alone for 12 weeks. CBASP plus pharmacotherapy was associated with significantly greater improvement in social problem solving than BSP plus pharmacotherapy, and a trend for greater improvement in problem solving than pharmacotherapy alone. In addition, change in social problem solving predicted subsequent change in depressive symptoms over time. However, the magnitude of the associations between changes in social problem solving and subsequent depressive symptoms did not differ across treatment conditions. It does not appear that improved social problem solving is a mechanism that uniquely distinguishes CBASP from other treatment approaches.
    Journal of Consulting and Clinical Psychology 06/2011; 79(3):342-52. DOI:10.1037/a0023208 · 4.85 Impact Factor
  • Source
    • "Intensive, evidence-based approaches specifically tailored for chronic MDD (e.g. Keller et al. 2000; Schatzberg et al. 2005) may hold more promise in reducing its course and attendant psychosocial impairments. Given the overlap between MDD course and substance use disorder episodes and anxiety disorder duration respectively, treatment providers may also assess and intervene for these co-occurring disorders (Watkins et al. 2006; Zimmerman et al. 2006). "
    [Show abstract] [Hide abstract]
    ABSTRACT: Research on the long-term course of major depressive disorder (MDD) is hindered by the absence of established course criteria and by idiosyncratic definitions of chronicity. The aims of this study were to derive an empirical index of MDD course, to examine its predictive validity, and to identify the adulthood outcomes associated with a chronic course. Indicators for a MDD course factor were rationally selected and subjected to principal components (PCA) and confirmatory factor analyses (CFA) among 426 subjects with a lifetime history of MDD by age 30. Scores on the index prior to age 19 were examined as predictors of course from age 19 to 30. Associations between the index and outcomes of interest at age 30 were examined. Three indicators loaded highly on a chronic course index and displayed adequate internal consistency: early onset age, number of episodes, and duration of ill time. Predictive validity of the index was supported. A more chronic course was associated with greater symptom severity, greater likelihood of treatment utilization, and greater psychosocial impairment in multiple domains. Treatment utilization interacted with chronicity to predict relatively few outcomes and did not reduce the negative impact of a chronic course. The course of MDD through early adulthood is best represented by a composite of early onset age, number of episodes, and duration of ill time. A chronic course through early adulthood is associated with numerous indicators of psychosocial impairment. Mental health treatment utilization in a naturalistic setting does not appear to reduce the negative impact of chronic MDD.
    Psychological Medicine 08/2008; 39(3):403-12. DOI:10.1017/S0033291708003851 · 5.43 Impact Factor
Show more